Peptide LibraryPemvidutide
Also known as: ALT-801, GLP-1/glucagon dual agonist
Pemvidutide (also called ALT-801 or GLP-1/glucagon dual agonist) is a glucagon agonist in the GLP-1 Agonist class. Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class.
For research use only.
Key Facts
- CAS
- 2538014-94-5
- Molecular Weight (MW)
- ≈4094 g/mol
- Half-life
- ~110 hours (EuPort™ albumin-binding domain; weekly dosing)
- FDA status
- Investigational New Drug (IND)
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Once weekly
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- GLP-1 receptorGlucagon receptor
Research summary
Investigational dual agonist at the GLP-1 and glucagon receptors from Altimmune, weighted toward glucagon activity relative to others in its class. It is in development for obesity and for metabolic dysfunction-associated steatohepatitis, where reducing hepatic fat is the therapeutic target. Not FDA-approved, and efficacy and safety remain under investigation.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials4 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Pemvidutide profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Pemvidutide dosage evidence
Pemvidutide has no approved dosage. Human dosing comes from Altimmune's trials of once-weekly injections under the skin of 1.2, 1.8 or 2.4 mg: in the IMPACT phase 2b trial in MASH with fibrosis, 1.2 mg and 1.8 mg without titration met the goal of MASH resolution at 24 weeks but not the fibrosis goal. A phase 3 MASH trial of 1.8 mg and 2.4 mg is recruiting.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 1.2–2.4 mg once weekly in trials |
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | 12–48 weeks in the reported trials |
| Titration | IMPACT gave its doses without titration. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| IMPACT — phase 2b, MASH with fibrosis (NCT05989711)Clinical trial · Randomized, double-blind, placebo-controlled phase 2b trial | Adults with biopsy-confirmed MASH and fibrosis stage F2–F3 (n=212) | 1.2 mg or 1.8 mg, without dose titration | Subcutaneous | Once weekly | 24-week results of a 48-week trial | MASH resolution without worse fibrosis in 58% (1.2 mg) and 52% (1.8 mg) against 20% with placebo; the fibrosis-improvement endpoint was not met | Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025. |
| Phase 1b, MASLD (NCT05006885)Clinical trial · Randomized, double-blind, placebo-controlled trial | Adults with BMI ≥28 and liver fat ≥10% (n=94) | 1.2, 1.8 or 2.4 mg | Subcutaneous | Once weekly | 12 weeks | Relative liver-fat reduction of 46.6%, 68.5% and 57.1% against 4.4% with placebo; weight change up to -4.3% at 1.8 mg | Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025. |
| MOMENTUM — phase 2, obesity (NCT05295875)Clinical trial · Phase 2 randomized, placebo-controlled trial | Adults with obesity (n=391) | Three dose levels; amounts not given in the registry | Subcutaneous | Per trial protocol | 48 weeks (primary endpoint) | Completed; no results posted on ClinicalTrials.gov | NCT05295875 — Efficacy and Safety of ALT-801 in the Treatment of Obesity |
| Phase 3, MASH outcomes (NCT07795164)Clinical trial · Phase 3 randomized, placebo-controlled trial | Adults with MASH (n=1,800 planned) | 1.8 mg or 2.4 mg | Subcutaneous | Per trial protocol | About 60 months for clinical outcomes; histology at week 52 | Recruiting; no results | NCT07795164 — Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH |
Where sources disagree
- IMPACT met one of its two primary endpoints (MASH resolution) but not the other (fibrosis improvement) at 24 weeks.
- The code ALT-801 was also used for an unrelated interleukin-2 fusion protein studied in cancer. Papers and registry entries about that ALT-801 are not evidence about pemvidutide.
- Pemvidutide is not FDA-approved.
Handling & administration
- Reconstitution Guide
- Investigational - not yet established
- Injection Sites
- AbdomenThighUpper arm
- Concentration Example
- Investigational - not yet established
- Timing Notes
- Investigational; follow trial schedule
- Expected Onset
- Investigational - onset under evaluation
Sequence & molecular data
| Molecular formula | C182H275N39O54 |
|---|---|
| Molecular weight | ≈4094 g/mol |
| CAS number | 2538014-94-5 |
| Half-life | ~110 hours (EuPort™ albumin-binding domain; weekly dosing) |
| Appearance | Lyophilized powder or solution for sc use (investigational) |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class. GLP-1 receptor activation reduces food intake through hypothalamic and brainstem circuits, while glucagon receptor activation increases hepatic energy expenditure and drives fatty-acid oxidation in the liver. That emphasis is the rationale for its investigation in metabolic dysfunction-associated steatohepatitis, where reducing hepatic lipid is the therapeutic target, as well as in obesity. It is investigational and not approved for any indication.
Origin
Synthetic peptide dual agonist.
Targets
Studies
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial
Research statistics
12 PubMed publications · 33.3% human clinical research · 16 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Pemvidutide has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
How FDA approval, compounding and research-only status differ
Benefits
Pemvidutide side effects
The effects below are those reported in Pemvidutide clinical trials; long-term safety data may still be limited.
Side Effects
- Nausea
- Vomiting
- Heart-rate increase possible
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Pemvidutide: frequently asked questions
What is Pemvidutide?
Investigational dual agonist at the GLP-1 and glucagon receptors from Altimmune, weighted toward glucagon activity relative to others in its class. It is in development for obesity and for metabolic dysfunction-associated steatohepatitis, where reducing hepatic fat is the therapeutic target. Not FDA-approved, and efficacy and safety remain under investigation.
How does Pemvidutide work?
Pemvidutide is a dual agonist at the GLP-1 and glucagon receptors with a deliberately weighted ratio favouring glucagon activity relative to other agents in the class. GLP-1 receptor activation reduces food intake through hypothalamic and brainstem circuits, while glucagon receptor activation increases hepatic energy expenditure and drives fatty-acid oxidation in the liver.
Is Pemvidutide FDA approved?
No. Pemvidutide is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of Pemvidutide?
Reported half-life for Pemvidutide is ~110 hours (EuPort™ albumin-binding domain; weekly dosing). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Pemvidutide banned in sport?
Pemvidutide is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Pemvidutide?
Compounds most often compared with Pemvidutide include Retatrutide, Survodutide, Cotadutide and Mazdutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials — Naunyn Schmiedebergs Arch Pharmacol, 2026External reference
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study — J Hepatol, 2025External reference
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study — Lancet, 2025External reference
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial — Lancet, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 3
This Pemvidutide profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Pemvidutide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →